



The Asian Pacific Association for the Study of the Liver



APASL Oncology 2021

*“Your Gateway to Oncology
in Asia-Pacific Region”*

Final Information



Term: December 17-18, 2021

City: Tokyo, Japan (Hybrid Meeting)

Onsite-Venue: The Prince Park Tower Tokyo

President: Mitsuhiro Moriyama, M.D.

Professor and Chairman,
Division of Gastroenterology and Hepatology,
Department of Internal Medicine,
Nihon University School of Medicine

世界中の人々の
より豊かな人生のため、
革新的医薬品に
思いやりを込めて

Lilly



日本イーライリリーは製薬会社として、
人々がより長く、より健康で、充実した生活を実現できるよう、
がん、糖尿病、筋骨格系疾患、中枢神経系疾患、自己免疫疾患、
成長障害、疼痛などの領域で、日本の医療に貢献しています。

日本イーライリリー株式会社

〒651-0086 神戸市中央区磯上通 5-1-28
www.lilly.co.jp

Canon

i が描く新たな地平。

アプリオが変わる。i-series が新しい頭脳を持つ。

最先端技術を搭載し、超音波診断装置に革新をもたらした i-series の誕生から5年。


Aplio i-series は、コアとなるCPU/GPUを刷新し、設計段階で機械学習を行い、
キャノンが培った先進の画像技術、ワークフロー、アプリケーションをより先鋭化しました。

超音波診断における、さまざまな診療領域・診断ニーズをハイレベル ワンストップで実現します。

Aplio i-series / Prism Edition の誕生です。



Image Quality



Application

Work flow

オールインワンの1台をキャノンから

Aplio i-series Prism Edition

※Ai: Aplio i-seriesの略です。

【一般的名称】 汎用超音波画像診断装置 【製造販売元】 キヤノンメディカルシステムズ株式会社

【販売名】 超音波診断装置 Aplio i700 TUS-AI700 【認証番号】 228ABBZX00022000 / 【販売名】 超音波診断装置 Aplio i800 TUS-AI800 【認証番号】 228ABBZX00021000

【販売名】 超音波診断装置 Aplio i900 TUS-AI900 【認証番号】 228ABBZX00020000

キヤノンメディカルシステムズ株式会社 <https://jp.medical.canon>

Made For life



APASL Oncology 2021 in Tokyo

“Your Gateway to Oncology in Asia-Pacific Region”

Hybrid Meeting (Onsite-Venue: The Prince Park Tower Tokyo)

December 17-18, 2021

Table of Contents

<u>Welcome Message</u>	<u>2</u>
<u>Invited Guest Speakers / Chairs / Scientific Committee</u>	<u>4</u>
<u>Organizing Committee</u>	<u>5</u>
<u>Conference Information</u>	<u>6</u>
<u>On-Site Venue</u>	<u>7</u>
<u>Instruction for Oral Presentation</u>	<u>8</u>
<u>Instruction for Chairs</u>	<u>9</u>
<u>Instruction for On-Site Poster Presentation</u>	<u>10</u>
<u>Instruction for E-Poster Presentation</u>	<u>11</u>
<u>Awards / Contact</u>	<u>12</u>
<u>Sponsors and Support Organization</u>	<u>14</u>
<u>Program at a Glance</u>	<u>16</u>
<u>Scientific Program</u>	<u>18</u>
<u>On-site Poster Session Program</u>	<u>33</u>
<u>E-Poster Session Program</u>	<u>37</u>

Welcome Message



Dear Colleagues,

It gives us great pleasure to welcome you to the Asian Pacific Association for the Study of the Liver APASL Oncology 2021.


Never in the history of humankind should we now be more united in our efforts to confront a common deadly enemy - COVID-19. To win this war for the human race, we need knowledge from all fronts, to be united in our critical thinking and experiences. So far, tremendous effort has been exercised to control new human transmission.

To this end, we APASL have organized frequent APASL Hepatology Webinars since last year and are webcasting those high-quality educational webinars through our official “APASL Cast” with a large number of registrants.

On the other side, as the new series of the APASL official meeting; Annual meeting and Single topic conferences with a variety of topics, the “APASL Oncology” meeting has been launched from this year, and this event marks the memorable 1st conference of “APASL Oncology” in Tokyo (hybrid-style meeting) focusing particularly on the study of “Hepatic Oncology”. We anticipate active discussion with experts in various field to enlighten us on the most recent Asia-Pacific data in epidemiology, diagnostics, treatment, and all of “Oncology”.

We look forward to your participation!

Yours sincerely,

A handwritten signature in black ink, appearing to read 'M. Omata'.

Masao Omata M.D.
Honorary President, APASL Oncology 2021 Tokyo
Steering Committee of APASL
Professor Emeritus, The University of Tokyo
President, Yamanashi Central and Kita Hospitals

Welcome Message



Dear Colleagues,

On behalf of the Organizing Committee, we would like to welcome you to the Asian Pacific Association for the Study of the Liver APASL Oncology 2021, which will be held on December 17-18 2021 in Tokyo, Japan as a hybrid-style meeting.

This conference had originally been scheduled for December 2020; however, it was rescheduled because of the COVID-19 pandemic. We deeply appreciate your understanding and cooperation.

The scientific program will consist of invited lectures, plenary sessions, symposia, and free papers on significant developments on the theme of “Your Gateway to Oncology in the Asia-Pacific Region”. The program will also provide the latest information and fresh ideas for hepatologists and oncologists in this area.

We have accepted all categories of Hepatology and Oncology abstracts, including case reports.

We appreciate your submission of abstracts and anticipate a large number of attendants, which will stimulate active discussions.

APASL Oncology 2021 will combine the physical event at The Prince Park Tower Tokyo, Japan in the Centre of Tokyo, with a Virtual Meeting platform for a unique experience bringing both the in-person and virtual community together. Webcast video presentations will be connected with physical presentations and sessions including virtual interactions, live commentary, online chat and discussion.

A delegation of experts from all over the world is expected to attend this conference. We are sure that this will provide an excellent opportunity for those of us in the Asian Pacific region to share the latest views, values, experience, and practice, and greatly contribute to this field.

We are looking forward to seeing you soon in Tokyo or through the online webinar.

With warmest regards,

A handwritten signature in dark ink, reading "Mitsuhiko Moriyama". The signature is fluid and cursive, with the first name "Mitsuhiko" and last name "Moriyama" clearly distinguishable.

Mitsuhiko Moriyama, M.D.

President, APASL Oncology 2021 Tokyo

Professor and Chairman, Division of Gastroenterology and Hepatology
Department of Internal Medicine, Nihon University School of Medicine

Invited Guest Speakers/Chairs/Scientific Committee

Invited Guest Speakers/Chairs/Scientific Committee from Overseas

Dr. Oidov Baatarkhuu (Mongolia)	Dr. Seth J. Karp (USA)	Dr. Gamal Shiha (Egypt)
Dr. Pei Jer Chen (Taiwan)	Dr. Do Young Kim (Korea)	Dr. Simone Strasser (Australia)
Dr. Ann-Lii Cheng (Taiwan)	Dr. George Lau (China)	Dr. Pil Soo Sung (Korea)
Dr. Wan Long Chuang (Taiwan)	Dr. Cosmas R.A. Lesmana (Indonesia)	Dr. Tung-Hung Su (Taiwan)
Dr. Massimo Colombo (Italy)	Dr. Chun-Jen Liu (Taiwan)	Dr. Tawesak Tanwandee (Thailand)
Dr. Levent Doğanay (Turkey)	Dr. Mamun-Al Mahtab (Bangladesh)	Dr. Arndt Vogel (Germany)
Dr. A. Kadir Dokmeci (Turkey)	Dr. Rakhi Maiwall (India)	Dr. Lai Wei (China)
Dr. Rino Gani (Indonesia)	Dr. Necati Örmeci (Turkey)	Dr. Jin Mo Yang (Korea)
Dr. Hasmik Ghazinyan (Armenia)	Dr. Young Nyun Park (Korea)	Dr. Thomas Yau (China)
Dr. Saeed Hamid (Pakistan)	Dr. Diana A. Payawal (Philippines)	Dr. Wei-Peng Yong (Singapore)
Dr. Jee-Fu Huang (Taiwan)	Dr. Teerha Piratvisuth (Thailand)	Dr. Changhoon Yoo (Korea)
Dr. Chiun Hsu (Taiwan)	Dr. Ranjit Ray (USA)	Dr. Hong You (China)
Dr. Washim Jafri (Pakistan)	Dr. Ratna B. Ray (USA)	Dr. Min-Lung Yu (Taiwan)
Dr. Ji Dong Jia (China)	Dr. Shiv Kumar Sarin (India)	Dr. Man-Fung Yuen (China)
Dr. Jia-Horng Kao (Taiwan)	Dr. Manoj K. Sharma (India)	

In alphabetical order

Invited Guest Speakers/Chairs/ Scientific Committee from Japan

Dr. Hiroyuki Aburatani	Dr. Shuichi Kaneko	Dr. Mitsuhiko Moriyama
Dr. Shinichi Aishima	Dr. Tatsuya Kanto	Dr. Kazunari Murakami
Dr. Norio Akuta	Dr. Hiroaki Kanzaki	Dr. Takamichi Murakami
Dr. Jun Arai	Dr. Mureo Kasahara	Dr. Akihito Nagahara
Dr. Yoshinari Asaoka	Dr. Naoya Kato	Dr. Hidenari Nagai
Dr. Kazuaki Chayama	Dr. Norifumi Kawada	Dr. Yuko Nagaoki
Dr. Tetsuhiro Chiba	Dr. Takumi Kawaguchi	Dr. Sumiko Nagoshi
Dr. Hirayuki Enomoto	Dr. Yusuke Kawamura	Dr. Hidewaki Nakagawa
Dr. Kenichi Harada	Dr. Kazufumi Kobayashi	Dr. Nobuhiro Nakamoto
Dr. Kiyoshi Hasegawa	Dr. Takahiro Kodama	Dr. Naoshi Nishida
Dr. Etsuro Hatano	Dr. Atsumasa Komori	Dr. Shuhei Nishiguchi
Dr. Yoichi Hiasa	Dr. Mina Komuta	Dr. Takuto Nosaka
Dr. Hayato Hikita	Dr. Yasuteru Kondo	Dr. Kazuhiro Nouse
Dr. Atsushi Hiraoka	Dr. Keisuke Koroki	Dr. Shuntaro Obi
Dr. Yosuke Hirotsu	Dr. Masatoshi Kudo	Dr. Sadahisa Ogasawara
Dr. Masao Honda	Dr. Masayuki Kurosaki	Dr. Masahiro Ogawa
Dr. Hiroko Iijima	Dr. Shinya Maekawa	Dr. Takamasa Ohki
Dr. Hiroo Imazu	Dr. Hitoshi Maruyama	Dr. Masayuki Ohtsuka
Dr. Yuji Iimuro	Dr. Tsutomu Masaki	Dr. Yukiyasu Okamura
Dr. Masafumi Ikeda	Dr. Ryota Masuzaki	Dr. Hironao Okubo
Dr. Sadakatsu Ikeda	Dr. Naoki Matsumoto	Dr. Masao Omata
Dr. Fumio Imazeki	Dr. Yutaka Midorikawa	Dr. Motoyuki Otsuka
Dr. Hiroo Imazu	Dr. Toshio Miki	Dr. Issei Saeki
Dr. Hideki Iwamoto	Dr. Masashi Mizokami	Dr. Michiie Sakamoto
Dr. Namiki Izumi	Dr. Eishiro Mizukoshi	Dr. Naoya Sakamoto
Dr. Kenya Kamimura	Dr. Satoshi Mochida	Dr. Reina Sasaki
Dr. Tatsuo Kanda	Dr. Naoki Morimoto	Dr. Shinpei Sato

Dr. Shuichiro Shiina	Dr. Makiko Taniai	Dr. Taro Yamashita
Dr. Masahito Shimizu	Dr. Ryosuke Tateishi	Dr. Tatsuya Yamashita
Dr. Masaya Sugiyama	Dr. Katsutoshi Tokushige	Dr. Shintaro Yamazaki
Dr. Fumitaka Suzuki	Dr. Takuji Torimura	Dr. Yutaka Yasui
Dr. Shinichi Takahashi	Dr. Hidenori Toyoda	Dr. Hiroshi Yatsuhashi
Dr. Tadatoshi Takayama	Dr. Kaoru Tuchiya	Dr. Osamu Yokosuka
Dr. Haruhiko Takeda	Dr. Yoshiyuki Ueno	Dr. Hideo Yoshida
Dr. Tetsuo Takehara	Dr. Kazuomi Ueshima	Dr. Hitoshi Yoshiji
Dr. Junko Tanaka	Dr. Takeji Umemura	Dr. Sachiyo Yoshio
Dr. Shinji Tanaka	Dr. Yoshiyuki Wada	Dr. Hiroshi Yotsuyanagi
Dr. Yasuhito Tanaka	Dr. Takuya Yamagishi	

In alphabetical order

Organizing Committee

Local Organizing Committee

Honorary President: Dr. Masao Omata	Treasurer: Dr. Fumio Imazeki
President: Dr. Mitsuhiro Moriyama	Vice-Treasurer: Dr. Shunichi Matsuoka
Vice-President: Dr. Tadatoshi Takayama	Vice-Treasurer: Dr. Masahiro Ogawa
Secretary General: Dr. Tatsuo Kanda	Vice-Secretary General: Dr. Ryota Masuzaki

APASL Steering Committee

Chairman of Steering Committee:	Dr. Shiv Kumar Sarin (India)
President:	Dr. Jin Mo Yang (Korea)
Immediate Past President:	Dr. Tawesak Tanwandee (Thailand)
President Elect:	Dr. Han-Chieh Lin (Taiwan)
Secretary General-cum-Treasurer:	Dr. Manoj K Sharma (India)
Past Presidents:	
Dr. Laurentius A. Lesmana (Indonesia)	Dr. Darrell Crawford (Australia)
Dr. Jose Sollano (Philippines)	Dr. A. Kadir Dokmeci (Turkey)
Dr. Masao Omata (Japan)	Dr. Osamu Yokosuka (Japan)
Dr. Dong Jin Suh (Korea)	Dr. Jinlin Hou (China)
Dr. George Lau (China)	Dr. Barjesh Chander Sharma (India)
Dr. Ji Dong Jia (China)	Dr. Diana A. Payawal (Philippines)
Dr. Teerha Piratvisuth (Thailand)	Dr. Rino Gani (Indonesia)
Dr. Jia-Horng Kao (Taiwan)	

APASL Executive Council

Assistant Secretary:	Dr. Hong You (China)
Executive Councils:	
Dr. Gulnara Aghayeva (Azerbaijan)	Dr. Simone Strasser (Australia)
Dr. Chun-Jen Liu (Taiwan)	Dr. Yaman Tokat (Turkey)
Dr. Mamun-Al-Mahtab (Bangladesh)	Dr. Yoshiyuki Ueno (Japan)
Dr. Rakhi Maiwall (India)	

Conference Information

Registration Fee and Category

	Pre-Registration until Dec. 10, 2021	On Site
APASL Member*	JPY 25,000	JPY 30,000
	Online: JPY 15,000	Online: JPY 15,000
Non-Member	JPY 35,000	JPY 40,000
	Online: JPY 15,000	Online: JPY 15,000
Trainee / Resident**	JPY 20,000	JPY 20,000
	Online: JPY 15,000	Online: JPY 15,000
Accepted Abstract Submitter	JPY 10,000	JPY 10,000
	Online: JPY 10,000	Online: JPY 10,000
Accompanying Person	JPY 5,000	JPY 5,000

JPY=Japanese Yen

*APASL Members who have paid 2021 Membership Fee can apply for discounted registration fee.

*Registration for viewing of On-demand Presentation is available until January 20th 2022.

Online Participation (Style: Zoom Webinar)

- The conference program will be presented as a hybrid style meeting.
- Attendants are able to enter the webinar through Zoom <https://zoom.us/join> with the ID and Password of which they have been informed by the conference secretariat. * For Speakers/Chairs, the secretariat sends an individual invitation link to enter the webinar.
- The lectures will be delivered live or by recorded video. After the presentation, the discussion (Q&A) time will be held according to the moderator's instructions. Online viewers are able to send textual questions to the Q&A column, and the onsite participants may ask questions using the microphone in the conference room. We anticipate your active discussions.
- After the conference term, the recorded lectures and discussion will be distributed on-demand from the presentation page of APASL Oncology 2021 Website <http://www.apasl-oncology2021.org/>
The viewing period of the on-demand presentation is scheduled to be from December 20, 2021 through January 20, 2022. The secretariat will receive the questions by e-mail during the on-demand delivery period and will forward them to each speaker.

[Precautions]

- The organizer cannot handle problems such as computer operation, internet connection, video and audio connection. Please solve such problems by yourself. We recommend the following environment.
 - We would appreciate it if you could use a PC with as much memory as possible (CPU i5 or more, memory 8 Giga or more).
 - Please connect to the Internet via a wired LAN line as much as possible.
 - To transfer or share the ID and password, recording of screens and images is strictly prohibited.
 - The internet fee at this online conference will be borne by each attendant.
- We cordially solicit your understanding and cooperation.

Onsite Registration/PC Pre-view Hours

December 17 (Friday) 7:30-19:30 (JST)

December 18 (Saturday) 7:30-16:00 (JST)

Onsite-Venue

The Prince Park Tower Tokyo

Address: 4-8-1 Shibakoen Minato, Tokyo 105-8563 Japan

Tel: +81-(0)3-5400-1111

URL: <http://www.princehotels.com/parktower/>

Location: [From Haneda Airport]

By Train: About 35 minutes to Daimon Station of Toei Subway Asakusa Line (via Keikyu Airport Line and Keikyu Line, Toei Subway Asakusa Line)

By Monorail: About 20 minutes by Tokyo Monorail to Hamamatsucho Station

By Car: About 15 minutes by taxi during normal hours (taking toll road, via Shibakoen Ramp)

[From Nearest Stations]

From Akabanebashi Station of Toei Subway Oedo Line: about 2 minutes on foot

From Shibakoen Station of Toei Subway Mita Line: about 3 minutes on foot


From Daimon Station of Toei Subway Asakusa Line/ Toei Subway Oedo Line: about 9 minutes on foot

From Hamamatsucho Station of JR Line/Tokyo Monorail: about 12 minutes on foot

From Kamiyacho Station of Tokyo Metro Subway Hibiya Line: about 12 minutes on foot



Floor Plan: B2F, The Prince Park Tower Tokyo



Instruction for Oral Presentation

The conference program will be presented as a hybrid style meeting.

- An invitation email containing information about the login will be sent to the presenters/moderators through the Zoom system. The login URL will be included in the invitation email.
- We would appreciate it if you could conduct a test connection ahead of the conference.
- The general sessions' presentation time is 15 minutes. The Oral Free Paper is 7 minutes (5 minutes presentation, 2 minutes discussion).
- After presentation, the discussion time (a question-and-answer session) will be held according to the moderator's instructions.

[For those who will participate at the onsite venue]

- Please complete your registration of presentation data at the Data Pre-View Desk until 1 hour before your presentation time.
- Please be seated at the "next speaker's seat" at least 10 minutes before your presentation. The seat will be located forward near the podium.
- The slides which you have submitted in advance for the presentation are prepared on the computer of the podium. Please operate the slides by yourself. Please note that the presenter tool is not available.
-

[For those who will attend online]

- Please join Zoom at least 20 minutes before your session begins.
- Please turn on the microphone and the camera only when you are speaking.
- The moderator will introduce the presenter at the beginning of each presentation.
- Then, the secretariat will start the presentation video. (In principle, you do not have to share your presentation by yourself.)
- After finishing the presentation, online viewers will send textual questions to the Q & A column, so please follow the moderator's instructions and answer those questions.
- The following environment is recommended.
 - Create the image resolution in XGA (1024 x 768).
 - Microsoft PowerPoint (2010-2016) can be used as the application software.
 - The fonts that come standard with Microsoft PowerPoint, Times, Arial are recommended.

[Precautions]

- Do not post, modify, distribute or reproduce copyrighted material, trademarks, portrait rights or other property rights in any way without the prior written consent of the owners of these property rights.
- Regarding citations, please specify the source of the citation.
- Please exert caution regarding the protection of personal information such as name, age, surgery date, etc. This could lead to the identification of an individual.

Instruction for Chairs

The conference program will be presented as a hybrid style meeting.

- An invitation email that contains information about the login will be sent to the presenters/moderators through the Zoom system. The login URL will be included in the invitation email.
- At the real time webinar, the recorded lecture will be presented, and speakers/chairs are requested to join the discussion time. The presentation and Q & A session will be delivered live.
- The general oral presentation time is 15 minutes. The Oral Free Paper is 7 minutes (5 minutes presentation, 2 minutes discussion).
- After presentation, the discussion time (a question-and-answer session) will be held according to the moderator's instructions. The online viewer will send questions in the Q & A column. The onsite participants will ask questions using the microphone at the conference hall.
- After the conference, the recorded video will be posted on the on-demand presentation page.

[For Chairs who will participate at the onsite conference venue]

Please be seated at the “next chair’s seat” at least 10 minutes before the session will start. The seat will be located forward near the stage.

[For Chairs who will attend online]

- Please join Zoom at least 20 minutes before your session begins.
- Please turn on the microphone and the camera only when you are speaking. Please mute the microphone otherwise.
- Please introduce the presenter at the beginning of each presentation. Then, the secretariat will start the presentation video, or the speaker will start his/her presentation on-site.
- After finishing the presentation, please turn on the microphone and camera again. Online viewers will send textual questions to the Q&A column, and the onsite participants will ask questions using the microphone in the conference room. So please convey those questions and moderate the discussion.
- The following environment is recommended.
 - Create the image resolution in XGA (1024 x 768).
 - Microsoft PowerPoint (2010-2016) can be used as the application software.
 - The fonts that come standard with Microsoft PowerPoint, Times, Arial are recommended.


Instruction for On-Site Poster Presentation

[About presentation style]

- A panel width 90cm×length 210cm will be provided for each poster as following sample.
- Poster number will be prepared by secretariat.
- Title and author's name are required to be prepared by each presenter.
- Pins for display will be provided at each poster panel.
- Location: Poster Session will be located in (or foyer of) the Room 4, B2 Floor, The Prince Park Tower Tokyo.
- Schedule: On-site Poster Presentation is scheduled as follows.

Poster Attachment:	7:30-11:00 on December 17 (Friday)
Poster Presentation:	13:40-14:20 on December 18 (Saturday)
Poster Removal:	16:00-17:30 on December 18 (Saturday)
- Presentation Time: 5 minutes (3 minutes presentation; 2 minutes discussion) for each presentation.
- For those who have not removed posters until above removal time, please accept that the secretariat will discard any posters that have remained.
- Awarding Ceremony: The Awardees will be presented at the Closing Ceremony during 17:40-17:50 on December 18 (Saturday).

Poster Panel



Instruction for E-Poster Presentation

[About presentation style]

The conference program will be presented as a hybrid style meeting.

The poster presenters who are not able to attend physically to the conference venue, are requested to present as the E-Poster.

- The E-Poster session will be available through APASL Oncology 2021 Website from the conference term at <http://www.apasl-oncology2021.org>
- After the conference, the presentation will be posted on the on-demand presentation page.
- Please send your presentation (PowerPoint File 4:3) in advance to the secretariat as follows.
- Microsoft PowerPoint (2010-2016) can be used as the application software.
- File size is limited to 20 MB.
- The number of PPT slides is limited to 15 slides including the title and COI slides.
- Requested PowerPoint size is 4: 3.
- Awarding Ceremony: The Awardees will be presented at the Closing Ceremony during 17:40-17:50 on December 18 (Saturday).

[Precautions]

- Do not post, modify, distribute, or reproduce copyrighted material, trademarks, portrait rights, or other property rights in any way without the prior written consent of the owners of these property rights.
- Regarding citations, please specify the source of the citation.
- Please exert caution regarding the protection of personal information such as name, age, surgery date, etc. This could lead to the identification of an individual.
- Please pay particular attention to images that may be considered problematic when viewed by the public at this conference.

If you have any questions, please contact the secretariat below.

Contact: APASL Oncology 2021 Tokyo Congress Secretariat

c/o Academia Support Japan

Email: info@apasl-oncology2021.org

Tel: +81-3-6380-0102 Fax: +81-3-6380-0103

URL <http://www.apasl-oncology2021.org>

Awards

Excellent papers will be awarded as “Presidential Award” or “Young Investigator Award”.

Awarding Ceremony: The Awardees of Free Papers will be presented at the Closing Ceremony during 17:40-17:50 (Japan Standard Time) on December 18 (Saturday).

Presidential Award

“APASL Oncology 2021 Presidential Award” will be awarded to whom performed the most excellent presentation in APASL Oncology 2021 to encourage to further their research and progress.

Young Investigator Award (Under 40 years old)

The purpose of the “APASL Oncology 2021 Young Investigator Award” is to praise outstanding examples of excellence amongst those involved in research training in the early stages of their career.

Contact

APASL Oncology 2021 Scientific Secretariat

Division of Gastroenterology and Hepatology

Department of Internal Medicine, Nihon University School of Medicine

APASL Oncology 2021 Congress Secretariat

c/o Academia Support Japan

Email: info@apasl-oncology2021.org

Tel: +81-3-6380-0102 Fax: +81-3-6380-0103

APASL Central Office (APASL Secretariat-Tokyo)

Asian Pacific Association for the Study of the Liver [APASL]

1-24-7-920, Shinjuku, Shinjuku-ku, Tokyo, 160-0022 Japan

Email: apasl_secretariat@apasl.info


Tel: +81-3-5312-7686 Fax: +81-3-5312-7687

This image shows a full page of a handwriting practice worksheet. It consists of multiple sets of three horizontal dashed lines, providing a guide for letter height and placement. The lines are evenly spaced across the entire page, leaving ample room for writing practice. There is no text or other markings on the page.

Sponsors and Support Organization

The Organizing Committee of the APASL Oncology 2021 Tokyo would like to express sincere gratitude to the following sponsors and organizations for supporting this conference.

Diamond Sponsor



Chugai Pharmaceutical Co., Ltd.

Platinum Sponsor



AbbVie GK

Gold Sponsors



Eisai Co., Ltd.



Incyte Biosciences Japan GK



Miyarisan Pharmaceutical Co., Ltd.



MSD K.K.



Sysmex Corporation

Silver Sponsors

AstraZeneca	Otsuka Pharmaceutical Co., Ltd.
Gilead Sciences K.K.	Takeda Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation	Towa Pharmaceutical Co., Ltd.

Mitsuwadai General Hospital

In alphabetical order

Bronze Sponsors

Akiru Municipal Medical Center	Mikuni Naika-Ganka Clinic
Ando Hospital Medical Corporation	Mochida Pharmaceutical Co., Ltd.
Asahi Kasei Pharma Corporation	Mylan EPD G.K.
ASKA Pharmaceutical Co., Ltd.	NexusAgent.inc
Astellas Pharma Inc.	Niiza Shiki Central General Hospital
Bayer Yakuhin, Ltd.	Nippon Boehringer Ingelheim Co., Ltd.
Canon Medical Systems	Nobelpharma Co., Ltd.
Chikuma Central Hospital	Nonakatokokai Seifuso Hospital
Cytori Therapeutics Inc.	Philips Japan, Ltd.
Daiichi Sankyo Co., Ltd.	Shino-Test Corporation
Dainippon Sumitomo Pharma Co., Ltd.	Stryker Japan K.K.
Eli Lilly Japan K.K.	Syoutokukai Sekishindo Hospital
Honda R&D Co., Ltd.	Terumo Corporation
Inogashira Corporation	TKP Medicalink Corporation
Janssen Pharmaceutical K.K.	Tokyo Health Service Association
Medikit Co., Ltd.	ZERIA Pharmaceutical Co., Ltd.

In alphabetical order

Support Organizations

Alumni Association, Nihon University School of Medicine

The Japan Society of Hepatology

Tokyo Convention & Visitors Bureau

The Uehara Memorial Foundation

In alphabetical order

Program at a Glance

Day 1: December 17 (Friday) 2021

Time (JST)	Day 1 (December 17 Friday) 2021				
	Room 1 (A+B)	Room 2 (C)	Room 3 (D)	Room 4 (E)	Web
7:50	Opening Ceremony				
8:00	8:00-9:00 Morning Seminar (1) (Chugai Pharmaceutical Co., Ltd.)	8:00-9:00 Morning Seminar (2) (Otsuka Pharmaceutical Co., Ltd.)		Poster Set up	E-Poster Presentation
9:00					
10:00	9:10-10:40 Session 1 Molecular Mechanism of HCC (1)	9:05-10:50 Session 6 Surgery and Transplantation	9:10-10:06 Oral Free Papers (1)	Poster Viewing	
11:00					
12:00	10:50-12:20 Session 2 Intermediate-stage HCC (1)	11:00-12:30 Session 7 HCC in Asia, Epidemiology (1)			
13:00	12:30-13:30 Luncheon Seminar (1) (Chugai Pharmaceutical Co., Ltd.)	12:40-13:40 Luncheon Seminar (2) (Sysmex Co., Ltd.)	12:30-13:30 Luncheon Seminar (3) (Eisai Co., Ltd. / MSD K.K.)		
14:00	13:40-14:20 President Lecture (Towa Pharmaceutical Co., Ltd.)				
15:00	14:30-16:00 Session 3 Intermediate-stage HCC (2)	14:30-16:00 Session 8 HCC in Asia, Epidemiology (2)	14:30-15:30 Educational Seminar (1) (Miyarisan Pharmaceutical Co., Ltd.)		
16:00			15:40-16:50 Oral Free Papers (2)		
17:00	16:10-17:40 Session 4 Pathology of HCC	16:10-17:40 Session 9 Management of HCC and Complications during TKI Treatment			
18:00	17:50-19:20 Session 5 Oncoimmunotherapy for HCC	17:50-19:20 Session 10 HCC after SVR			
19:00					
20:00	19:30-20:30 Evening Seminar (Incyte Biosciences Japan GK)				
22:30		20:00-22:30 APASL Hepatology Webinar “Editor’s Choice” collaborated with AASLD			

Program at a Glance

Day 2: December 18 (Saturday) 2021

Time (JST)	Day 2 (December 18 Saturday) 2021				
	Room 1 (A+B)	Room 2 (C)	Room 3 (D)	Room 4 (E)	Web
8:00	8:00-9:00 Morning Seminar (3) (Mitsubishi Tanabe Pharma Corporation)	8:00-9:00 Morning Seminar (4) (Takeda Pharmaceutical Co., Ltd.)	8:00-9:00 Morning Seminar (5) (AstraZeneca)	Poster Viewing	E-Poster Presentation
9:00					
10:00	9:10-10:40 Session 11 Molecular Mechanism of HCC (2)	9:10-10:40 Session 15 COVID-19 in Japan	9:10-10:40 Oral Free Papers (3)		
11:00					
12:00	10:50-12:20 Session 12 HAIC, TACE, RFA, Radiation	10:50-12:20 Session 16 Diagnosis of HCC	11:00-12:00 Educational Seminar (2) (AbbVie GK)		
13:00	12:30-13:30 Luncheon Seminar (4) (AbbVie GK)	12:30-13:30 Luncheon Seminar (5) (Gilead Sciences K.K.)			
14:00					
15:00	14:30-16:00 Session 13 Intermediate-stage HCC (3)	14:30-16:00 Session 17 Intermediate-stage HCC (4)		13:40-14:20 Poster Presentation	
16:00				Poster Viewing	
17:00	16:10-17:40 Session 14 Intermediate-stage HCC (5)	16:10-17:40 Session 18 Intermediate-stage HCC (6)		Poster Removal	
18:00	17:40-17:50 Awarding Ceremony				
	17:50-18:00 Closing Ceremony				

Scientific Program

Day 1: December 17 (Friday) 2021

Room 1

7:50-8:00 Opening Ceremony

Dr. Mitsuhiro Moriyama (President of APASL Oncology 2021)

8:00-9:00 Morning Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)

Chair: Dr. Masao Omata (Japan)

Toward Further Advancement of Molecular Targeted Therapy Using Liquid Biopsy in HCC

Dr. Sadakatsu Ikeda (Japan)

9:10-10:40 Session 1: Molecular Mechanism of HCC (1)

Chairs: Dr. Ranjit Ray (USA)/Dr. Naoshi Nishida (Japan)

9:10-9:25 1-1 Risk Assessment of Hepatocellular Carcinoma Development-clinical and Molecular Perspective

Dr. Ryota Masuzaki (Japan)

9:25-9:40 1-2 Role of FGF19/FGFR4 Signaling and Potential of Serum FGF19 as a Biomarker in Hepatocellular Carcinoma

Dr. Tetsuhiro Chiba (Japan)

9:40-9:55 1-3 Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression

Dr. Yutaka Midorikawa (Japan)

9:55-10:10 1-4 Linking lncRNA Linc-Pint with Liver Disease

Dr. Ratna B. Ray (USA)

10:10-10:25 1-5 Genetic and Epigenetic Basis of Pediatric Liver Tumors

Dr. Hiroyuki Aburatani (Japan)

10:25-10:40 Discussion Time

10:50-12:20 Session 2: Intermediate-stage HCC (1) (TKI, Lenvatinib)

Chairs: Dr. Tawesak Tanwandee (Thailand)/Dr. Masafumi Ikeda (Japan)

10:50-11:05 2-1 Analysis for Transition of Molecular Target Agent Therapy and Prognosis in Advanced Hepatocellular Carcinoma

Dr. Kazufumi Kobayashi (Japan)

11:05-11:20 2-2 HCC Following Hepatitis C Virus Eradication

Dr. Massimo Colombo (Italy)

11:20-11:35 2-3 Integrating Systemic Therapy into Multidisciplinary Treatment of HCC

Dr. Ann-Lii Cheng (Taiwan)

- 11:35-11:50 **2-4 Systemic Treatment Including Lenvatinib in Patients with BCLC-B Stage Hepatocellular Carcinoma**
 Dr. Atsushi Hiraoka (Japan)
- 11:50-12:05 **2-5 Identification of Tumor Factors of Hepatocellular Carcinoma that Decrease the Efficacy of Immune Checkpoint Inhibitors**
 Dr. Masao Honda (Japan)
- 12:05-12:20 Discussion Time

12:30-13:30 Luncheon Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)

Chair: Dr. Masatoshi Kudo (Japan)

Novel Cancer Immunotherapy for Hepatocellular Carcinoma: Evidence and Management

Dr. Masafumi Ikeda (Japan)

Exploring Next-Gen Systemic Therapy for HCC: What Have We Learned?

Dr. Ann-Lii Cheng (Taiwan)

13:40-14:20 President Lecture (Sponsored by Towa Pharmaceutical Co., Ltd.)

Chair: Dr. Masao Omata (Japan)

Considering the Occurrence of Liver Cancer from Chronic Hepatitis C / Cirrhosis in Japan

Dr. Mitsuhiro Moriyama (President of APASL Oncology 2021)

14:30-16:00 Session 3: Intermediate-stage HCC (2)

Chairs: Dr. George Lau (China)/Dr. Atsumasa Komori (Japan)/Dr. Tsutomu Masaki (Japan)

- 14:30-14:45 **3-1 Treatment Strategy for Intermediate Stage HCC**
 Dr. Masafumi Ikeda (Japan)
- 14:45-15:00 **3-2 Paradigm Shift with Drug Therapy in the Treatment of Intermediate-Stage Hepatocellular Carcinoma**
 Dr. Tatsuya Yamashita (Japan)
- 15:00-15:15 **3-3 Treatment Strategy for Intermediate Stage HCC with Consideration of Maintaining Liver Function**
 Dr. Naoya Kato (Japan)
- 15:15-15:30 **3-4 Systemic Therapy in the Intermediate Stage HCC: Current Evidence and Future Perspective**
 Dr. Changhoon Yoo (Korea)
- 15:30-15:45 **3-5 Treatment Strategy of Intermediate-stage HCC: ABC Conversion Therapy**
 Dr. Masatoshi Kudo (Japan)
- 15:45-16:00 Discussion Time

16:10-17:40 Session 4: Pathology of HCC

Chairs: Dr. Shinichi Aishima (Japan)/Dr. Kenichi Harada (Japan)/Dr. Michiie Sakamoto (Japan)

- 16:10-16:25 **4-1 Tumour Heterogeneity of HCC and Its Clinical Relevance**
 Dr. Mina Komuta (Japan)

16:25-16:40	4-2 Pathological Features of Tumor Microenvironment of HCC Dr. Michiie Sakamoto (Japan)
16:40-16:55	4-3 Genomic Structures and Carcinogenesis of HBV Integrations in Liver Cancer Dr. Hidewaki Nakagawa (Japan)
16:55-17:10	4-4 Update in HCC Pathology Dr. Young Nyun Park (Korea)
17:10-17:25	4-5 Morphological Subtypes of Hepatocellular Carcinoma Dr. Shinichi Aishima (Japan)
17:25-17:40	Discussion Time

17:50-19:20 Session 5: Oncoimmunotherapy for HCC

Chairs: Dr. Shiv K. Sarin (India)/Dr. Masao Omata (Japan)

17:50-18:05	5-1 Mechanism of Resistance to Immunotherapy for Hepatocellular Carcinoma Dr. Kazuomi Ueshima (Japan)
18:05-18:20	5-2 Dramatic Transformation of Treatments in Patients with Advanced Hepatocellular Carcinoma Dr. Sadahisa Ogasawara (Japan)
18:20-18:35	5-3 Oncoimmunotherapy for HCC (Tentative) Dr. Thomas Yau (China)
18:35-18:50	5-4 Leukotrienes Derived from Tumor-Infiltrating M2 Macrophages Promote the Progression of Hepatocellular Carcinoma Dr. Takuto Nosaka (Japan)
18:50-19:05	5-5 Multiomics Profiling Identifies the Link between Intra-tumor Steatosis and Immune-exhaustion in Non-viral HCC Dr. Takahiro Kodama (Japan)
19:05-19:20	Discussion Time

19:30-20:30 Evening Seminar (Sponsored by Incyte Biosciences Japan GK)

Chair: Dr. Yukiyasu Okamura (Japan)

New Personalized Approach for Intrahepatic Cholangiocarcinoma Based on Cancer Genomic Diagnosis in Japan

Dr. Naoya Kato (Japan)

Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions

Dr. Arndt Vogel (Germany)

Day 1: December 17 (Friday) 2021

Room 2

8:00-9:00 Morning Seminar (2) (Sponsored by Otsuka Pharmaceutical Co., Ltd.)

Chair: Dr. Naoya Kato (Japan)

The Usefulness of Tolvaptan as a Treatment of Hepatic Edema among Advanced HCC Patients

Dr. Takamasa Ohki (Japan)

Clinical Symptoms of Liver Diseases: Pathogenesis and Treatment

Dr. Tatsuo Kanda (Japan)

9:05-10:50 Session 6: Surgery and Transplantation

Chairs: Dr. Seth J. Karp (USA)/Dr. Tadatoshi Takayama (Japan)

9:05-9:20 **6-1 Placental Stem Cell Transplantation Prevented Disease Development in Ornithine Transcarbamylase Deficiency Model Mice**

Dr. Toshio Miki (Japan)

9:20-9:35 **6-2 Minimal Invasive Hepatectomy in the Post-SVR Era**

Dr. Yuji Iimuro (Japan)

9:35-9:50 **6-3 Surgery for Perihilar Cholangiocarcinoma: Resection and Transplantation**

Dr. Masayuki Ohtsuka (Japan)

9:50-10:05 **6-4 Management of Hepatocellular Carcinoma “Current Therapeutic Options”**

Dr. Washim Jafri (Pakistan)

10:05-10:20 **6-5 Proposal of Resectability for Hepatocellular Carcinoma for Future Clinical Trial**

Dr. Etsuro Hatano (Japan)

10:20-10:35 **6-6 Hepatoblastoma Management: From Resection To Transplantation**

Dr. Mureo Kasahara (Japan)

10:35-10:50 Discussion Time

11:00-12:30 Session 7: HCC in Asia, Epidemiology (1)

Chairs: Dr. Wan Long Chuang (Taiwan)/ Dr. Necati Örmeci (Turkey)/ Dr. Fumio Imazeki (Japan)

11:00-11:15 **7-1 HCC in China, Epidemiology (Tentative)**

Dr. Lai Wei (China)

11:15-11:30 **7-2 Epidemiological Aspects of HCC Prevention in Asia-Pacific**

Dr. Manoj K Sharma (India)

11:30-11:45 **7-3 Changing Epidemiology of Hepatocellular Carcinoma in Taiwan**

Dr. Wan-Long Chuang (Taiwan)

11:45-12:00 **7-4 The Magnified Challenge of HCC in Bangladesh in the Context of COVID-19 Pandemic**

Dr. Mamun-Al Mahtab (Bangladesh)

12:00-12:15 **7-5 HCC Caused by Hepatitis Delta Virus Infection in Asia-Pacific**

Dr. Saeed Hamid (Pakistan)

12:15-12:30 Discussion Time

12:40-13:40 Luncheon Seminar (2) (Sponsored by Sysmex Co., Ltd.)

Chair: Dr. Jia-Horng Kao (Taiwan)

M2BPGi for Liver Fibrosis and Outcome Prediction

Dr. Tung-Hung Su (Taiwan)

14:30-16:00 Session 8: HCC in Asia, Epidemiology (2)

Chairs: Dr. Hasmik Ghazinyan (Armenia) /Dr. Tatsuya Kanto (Japan)/Dr. Osamu Yokosuka (Japan)

14:30-14:45 8-1 Epidemiology Hepatocellular Carcinoma (HCC) in Thailand

Dr. Teerha Piratvisuth (Thailand)

14:45-15:00 8-2 Hepatocellular Carcinoma in Indonesia: Immunology View

Dr. Rino Gani (Indonesia)

15:00-15:15 8-3 Global Epidemiology & Risk Factors of Hepatocellular Carcinoma

Dr. Man-Fung Yuen (China)

15:15-15:30 8-4 Epidemiology of HCC in Mongolia

Dr. Oidov Baatarkhuu (Mongolia)

15:30-15:45 8-5 Epidemiology of Viral Hepatitis and HCC in Japan

Dr. Junko Tanaka (Japan)

15:45-16:00 Discussion Time

16:10-17:40 Session 9: Management of HCC and Complications during TKI Treatment

Chairs: Dr. A. Kadir Dokmeci (Turkey)/Dr. Diana A. Payawal (Philippines)/ Dr. Tetsuo Takehara (Japan)

16:10-16:25 9-1 HCC Treatment in JRCMC (Japanese Red Cross Medical Center)

Dr. Hideo Yoshida (Japan)

16:25-16:40 9-2 Management of Adverse Event from the Pharmacological Perspective in Patients with Hepatocellular Carcinoma Using Tyrosine Kinase Inhibitor

Dr. Hironao Okubo (Japan)

16:40-16:55 9-3 Management of HCC Patient with Portal Vein Thrombosis

Dr. Shiv Kumar Sarin (India)

16:55-17:10 9-4 Contrast-enhanced US-based Assessment of HCC Hemodynamics Related to Systemic Treatment

Dr. Hitoshi Maruyama (Japan)

17:10-17:25 9-5 Effective Prevention of TKI-related Vascular Damage induced Adverse Events and Maintenance of Hepatic Function by Dried Bonito Broth and Histidine

Dr. Kenya Kamimura (Japan)

17:25-17:40 Discussion Time

17:50-19:20 Session 10: HCC after SVR

Chairs: Dr. Shuhei Nishiguchi (Japan) /Dr. Yasuhito Tanaka (Japan)/ Dr. Hiroshi Yatsuhashi (Japan)

17:50-18:05 10-1 Rapid Hepatitis C Virus Clearance by Antivirals Correlates with Immune Status of Infected Patients and Decreased Immune Related Cytokines and Chemokines

Dr. Reina Sasaki (Japan)

18:05-18:20	10-2 The Clinical and Pathogenic Significance of HCC after Viral Eradication Dr. Min-Lung Yu (Taiwan)
18:20-18:35	10-3 Risk of Hepatocellular Carcinoma After Sustained Virological Response in Hepatitis C Virus Infection Dr. Yoichi Hiasa (Japan)
18:35-18:50	10-4 Development of HCC in Treated HBV Patients Dr. Jia-Horng Kao (Taiwan)
18:50-19:05	10-5 Gene Expression Signature Associated with HCC Development after HCV Eradication Dr. Yasuhito Tanaka (Japan)
19:05-19:20	Discussion Time

20:00-22:30 APASL Hepatology Webinar “Editor’s Choice” Collaborated with AASLD

Day 1: December 17 (Friday) 2021

Room 3

9:10-10:06 Oral Free Papers (1)

Chairs: Dr. Jun Arai (Japan)/Dr. Takumi Kawaguchi (Japan)/Dr. Naoya Sakamoto (Japan)

- 9:10-9:17 #10046 **Surgical Treatment for Multinodular HCC with Right Hepatic Vein Tumor Thrombosis: A Case Report**
Dr. Giang Nguyen (Viet Nam)
- 9:17-9:24 #10006 **A Case with HCC Successfully Treated with Prednisone for Atezolizumab-Associated Grade 3 Colitis**
Dr. Takahiro Fuji (Japan)
- 9:24-9:31 #10045 **New Research Trends in Onco-carcinogenesis and Nutritional Background Linked with Chronic Inflammation, Iron (Fe) Deposition, and Metabolic Changes**
Dr. Kenichi Furuya (Japan)
- 9:31-9:38 #10061 **Case reports of HCC with IVC and Rt. Atrium Tumor Thrombus and Extension into Left Renal Vein**
Dr. Parimita Barua (India)
- 9:38-9:45 #10005 **Novel Immuno-Oncotherapy against HCC by Targeting MICA**
Dr. Yumi Otoyama (Japan)
- 9:45-9:52 #10066 **Synergistic Nanoassemblies with Enhanced Cancer Chemo-Immunotherapy**
Dr. Xiaowei Shi (China)
- 9:52-9:59 #10012 **Various Uses of Ramucirumab in Real World Practice for Patients with Hepatocellular Carcinoma**
Dr. Naoya Kanogawa (Japan)
- 9:59-10:06 #10049 **Regorafenib and its metabolites could induce NK cell-mediated cytotoxicity in HCC by targeting ADAM9**
Dr. Jun Arai (Japan)

12:30-13:30 Luncheon Seminar (3) (Sponsored by Eisai Co., Ltd./MSD K.K.)

Chair: Dr. Shuntaro Obi (Japan)

LEN-TACE Sequential Therapy as a Therapeutic Strategy for Intermediate-stage Hepatocellular Carcinoma Dr. Yoshiyuki Wada (Japan)

Positioning of Hepatic Arterial Infusion Chemotherapy and Lenvatinib for Advanced Hepatocellular Carcinoma Dr. Tatsuya Yamashita (Japan)

14:30-15:30 Educational Seminar (1) (Sponsored by Miyarisan Pharmaceutical Co., Ltd.)

Chair: Dr. Tadatoshi Takayama (Japan)

Role of Gut Microbiota in Liver Disease and Carcinogenesis

Dr. Nobuhiro Nakamoto (Japan)

15:40-16:50 Oral Free Papers (2)

Chairs: Dr. Hidenari Nagai (Japan)/Dr. Yuko Nagaoki (Japan)

- | | | |
|-------------|--------|---|
| 15:40-15:47 | #10004 | Particle Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Dr. Yoshiro Matsuo (Japan) |
| 15:47-15:54 | #10024 | Efficacy and Safety of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma in Japan
Dr. Tadashi Namisaki (Japan) |
| 15:54-16:01 | #10020 | HCC Surveillance Remains Cost-effective Long after Hepatitis B Surface Antigen Loss: A 12-year Study
Dr. Terry Cheuk-Fung Yip (Japan) |
| 16:01-16:08 | #10064 | Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, 2019-2020
Dr. Hasmik Levon Ghazinyan (Armenia) |
| 16:08-16:15 | #10058 | Nucleic Acid Analog Therapy and Liver Carcinogenesis in Patients with Chronic Hepatitis B
Dr. Makoto Moriyama (Japan) |
| 16:15-16:22 | #10029 | Impact of Viral Eradication by DAA on Clinical Outcome after Treatment for HCV Associated HCC
Dr. Yuko Nagaoki (Japan) |
| 16:22-16:29 | #10047 | The Comprehensive Prognosis of Chronic Hepatitis C after DAA Therapy for Chronic Hepatitis C
Dr. Yuki Kanayama (Japan) |
| 16:29-16:36 | #10023 | Comparison of HBV Reactivation in HCC Patients Who Received TKI and TKI with PD-1 Inhibitor
Dr. Jin Lei (China) |
| 16:36-16:43 | #10067 | Occult Hepatitis B Virus Infection in Patients with HCV-Related Hepatocellular Carcinoma
Dr. Muhammad Abdel-Gawad (Egypt) |
| 16:43-16:50 | #10069 | Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease
Dr. Muhammad Abdel-Gawad (Egypt) |

Day 2: December 18 (Saturday) 2021

Room 1

8:00-9:00 Morning Seminar (3) (Sponsored by Mitsubishi Tanabe Pharma Corporation)

Chair: Dr. Katsutoshi Tokushige (Japan)

New Findings and Future Prospects, Based on Japanese Patients of Histological Proven NAFLD in Toranomon Hospital Dr. Norio Akuta (Japan)

9:10-10:40 Session 11: Molecular Mechanism of HCC (2)

Chairs: Dr. Lai Wei (China)/Dr. Shuichi Kaneko (Japan)/Dr. Shinji Tanaka (Japan)

- | | |
|-------------|--|
| 9:10-9:25 | 11-1 The Interaction of Hepatoma Cells and Stromal Cells Via IL-6 Family Cytokines
Dr. Hayato Hikita (Japan) |
| 9:25-9:40 | 11-2 Impairment of Homologous Recombination by HBx as the Mechanism for HBV-Related Hepatocarcinogenesis
Dr. Motoyuki Otsuka (Japan) |
| 9:40-9:55 | 11-3 Recent Progress in Basic and Clinical Research of Liver Cancer Stem Cells
Dr. Taro Yamashita (Japan) |
| 9:55-10:10 | 11-4 Genetic Alterations during Multistep Hepatocarcinogenesis Revealed by Whole Genome Sequencing
Dr. Haruhiko Takeda (Japan) |
| 10:10-10:25 | 11-5 Predictive Scores for Hepatocellular Carcinoma Risk Stratification after Achieving SVR Following DAAS
Dr. Gamal Shiha (Egypt) |
| 10:25-10:40 | Discussion Time |

10:50-12:20 Session 12: HAIC, TACE, RFA, Radiation

Chairs: Dr. Ji Dong Jia (China)/Dr. Satoshi Mochida (Japan)/Dr. Hitoshi Yoshiji (Japan)

- | | |
|-------------|--|
| 10:50-11:05 | 12-1 Radiofrequency Ablation for Hepatocellular Carcinoma
Dr. Ryosuke Tateishi (Japan) |
| 11:05-11:20 | 12-2 Hepatic Arterial Infusion Chemotherapy (HAIC) in 2021
Dr. Shuntaro Obi (Japan) |
| 11:20-11:35 | 12-3 Effective Use of Local Ablation Therapy for the Treatment of Early to Intermediate HCC
Dr. Kazuhiro Nouso (Japan) |
| 11:35-11:50 | 12-4 The Key Recommendations by APASL PBC Guidance 2021
Dr. Ji Dong Jia (China) |
| 11:50-12:05 | 12-5 Laparoscopic Radiofrequency Ablation in the Era of Non-viral Hepatitis
Dr. Naoki Morimoto (Japan) |
| 12:05-12:20 | Discussion Time |

12:30-13:30 Luncheon Seminar (4) (Sponsored by AbbVie GK)

Chair: Dr. Masayuki Kurosaki (Japan)

Ultra-FP Treatment could be Affordable Treatment Option for Advanced Stage of HCC

Dr. Yasuteru Kondo (Japan)

Antiviral Therapy for Hepatocellular Carcinoma: Primary and tertiary Prevention

Dr. Ryosuke Tateishi (Japan)

14:30-16:00 Session 13: Intermediate-stage HCC (3) (TKI, Sorafenib, Regorafenib)

Chairs: Dr. Manoj K Sharma (India)/Dr. Norifumi Kawada (Japan)

14:30-14:45 13-1 **Exploring Tumor Microenvironment in Patients with Advanced Hepatocellular Carcinoma**

Dr. Hiroaki Kanzaki (Japan)

14:45-15:00 13-2 **Management Challenges for Intermediate Stage Hepatocellular Carcinoma (HCC) in the Era of Systemic Therapy**

Dr. Cosmas Rinaldi A. Lesmana (Indonesia)

15:00-15:15 13-3 **Impact of Skeletal Muscle Volume in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) Receiving Sorafenib: A Comparison with Advanced HCC patients**

Dr. Issei Saeki (Japan)

15:15-15:30 13-4 **Mechanisms and Management of Sorafenib Resistance in Hepatocellular Carcinoma**

Dr. Rakhi Maiwall (India)

15:30-15:45 13-5 **Optimal Sequencing of TKI after Atezolizumab and Bevacizumab in HCC**

Dr. Wei-Peng Yong (Singapore)

15:45-16:00 Discussion Time

16:10-17:40 Session 14: Intermediate-stage HCC (5) (Ramucirumab, etc.)

Chairs: Dr. Pei Jer Chen (Taiwan)/ Simone Strasser (Australia)/Dr. Namiki Izumi (Japan)

16:10-16:25 14-1 **Systemic Therapy for Intermediate-stage Hepatocellular Carcinoma Including Real-world Data of Ramucirumab Treatment as Second or Later Line**

Dr. Yutaka Yasui (Japan)

16:25-16:40 14-2 **Analyses of Intermediate-stage Hepatocellular Carcinoma Patients Receiving TACE Prior to Designing Clinical Trials**

Dr. Keisuke Koroki (Japan)

16:40-16:55 14-3 **Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, January 2019 to March 2020 Nork Clinical Hospital of Infectious Diseases**

Dr. Hasmik Ghazinyan (Armenia)

16:55-17:10 14-4 **Management of Intermediate Hepatocellular Carcinoma - Past, Present and Future**

Dr. George Lau (China)

17:10-17:25	14-5 Treatment Strategy of Intermediate-stage HCC: LEN-TACE Sequential Therapy Dr. Masatoshi Kudo (Japan)
17:25-17:40	Discussion Time

17:40-17:50 Awarding Ceremony

17:50-18:00 Closing Ceremony

Dr. Mitsuhiro Moriyama (President of APASL Oncology 2021)

Day 2: December 18 (Saturday) 2021

Room 2

8:00-9:00 Morning Seminar (4) (Sponsored by Takeda Pharmaceutical Co., Ltd.)

Chair: Dr. Shinichi Takahashi (Japan)

Gastric Cancer Risk with H. Pylori Infection and Gastric Cancer Management in Japan

Dr. Kazunari Murakami (Japan)

9:10-10:40 Session 15: COVID-19 in Japan

Chairs: Dr. Masashi Mizokami (Japan)/Dr. Mitsuhiro Moriyama (Japan)

- | | |
|-------------|---|
| 9:10-9:25 | 15-1 Diagnosis, Genome Surveillance and Immune Response of COVID-19
Dr. Yosuke Hirotsu (Japan) |
| 9:25-9:40 | 15-2 Serum Predictive Factors for Severe Symptoms of COVID-19
Dr. Masaya Sugiyama (Japan) |
| 9:40-9:55 | 15-3 Management of Hepatocellular Carcinoma in the Era of COVID-19
Dr. Shuichiro Shiina (Japan) |
| 9:55-10:10 | 15-4 Responses to COVID-19 Outbreaks in Healthcare Setting in Japan, January 2020 - September 2021
Dr. Takuya Yamagishi (Japan) |
| 10:10-10:25 | 15-5 COVID-19 in Japan
Dr. Hiroshi Yotsuyanagi (Japan) |
| 10:25-10:40 | Discussion Time |

10:50-12:20 Session 16: Diagnosis of HCC

Chairs: Dr. Jee-Fu Huang (Taiwan)/Dr. Kiyoshi Hasegawa (Japan)/Dr. Masahiro Ogawa (Japan)

- | | |
|-------------|---|
| 10:50-11:05 | 16-1 Imaging Evaluation of HCC in the Systemic Treatment Era
Dr. Takamichi Murakami (Japan) |
| 11:05-11:20 | 16-2 Tumor Marker Profiles in Patients with Viral and Non-viral Hepatocellular Carcinoma
Dr. Hidenori Toyoda (Japan) |
| 11:20-11:35 | 16-3 Diagnosis of HCC (Tentative)
Dr. Do Young Kim (Korea) |
| 11:35-11:50 | 16-4 Diagnosis of Hepatocellular Carcinoma by Contrast-enhanced Ultrasound – Focusing on Early Hepatocellular Carcinoma
Dr. Hiroko Iijima (Japan) |
| 11:50-12:05 | 16-5 aMAP Score Prediction of Hepatocellular Carcinoma Development in Patients with Chronic Liver Disease
Dr. Takeji Umemura (Japan) |
| 12:05-12:20 | Discussion Time |

12:30-13:30 Luncheon Seminar (5) (Sponsored by Gilead Sciences K.K.)

Chair: Dr. Yoshiyuki Ueno (Japan)

Current Status of HBV Prevalence and Efforts for Eradicating Hepatic Failure by HBV Reactivation in Patients with Cancer Dr. Sachiyo Yoshio (Japan)

Recent Advances in Systemic Therapy for Hepatocellular Carcinoma and Management of Hepatitis B Infection Dr. Kaoru Tsuchiya (Japan)

14:30-16:00 Session 17: Intermediate-stage HCC (4) (TKI, Lenvatinib)

Chairs: Dr. Jin Mo Yang (Korea)/Dr. Kazuaki Chayama (Japan)/Dr. Takuji Torimura (Japan)

- 14:30-14:45 17-1 **Treatment Strategy of Intermediate Stage HCC using Lenvatinib “Lenvatinib TACE Sequential Therapy”**
Dr. Yusuke Kawamura (Japan)
- 14:45-15:00 17-2 **Lenvatinib for Intermediate Stage HCC**
Dr. Yoshinari Asaoka (Japan)
- 15:00-15:15 17-3 **The Dawn of a New Era in Hepatocellular Carcinoma Treatment with Molecular Targeted Therapy and Local Therapy**
Dr. Eishiro Mizukoshi (Japan)
- 15:15-15:30 17-4 **Adjuvant Systemic Therapies in Intermediate HCC**
Dr. Levent Doğanay (Turkey)
- 15:30-15:45 17-5 **Value of Lenvatinib in the Treatment of Intermediate Stage HCC**
Dr. Chun-Jen Liu (Taiwan)
- 15:45-16:00 Discussion Time

16:10-17:40 Session 18: Intermediate-stage HCC (6) (TKI, Lenvatinib)

Chairs: Dr. Sumiko Nagoshi (Japan)/Dr. Yoshiyuki Ueno (Japan)

- 16:10-16:25 18-1 **Contrast-enhanced Ultrasonography for Blood Flow Detection in Hepatocellular Carcinoma During Lenvatinib Therapy**
Dr. Naoki Matsumoto (Japan)
- 16:25-16:40 18-2 **Guidelines in Evolution: Systemic Therapy for Intermediate-stage HCC**
Dr. Chiun Hsu (Taiwan)
- 16:40-16:55 18-3 **Importance of Keeping Balance Between Therapeutic Effects and Adverse Events in Lenvatinib for Hepatocellular Carcinoma~Refinement of Administration Schedule and Combination with Transarterial Therapy~**
Dr. Hideki Iwamoto (Japan)
- 16:55-17:10 18-4 **Role of Tumor Immunogenicity and Tumor-associated Macrophages in Multi-kinase Inhibitor Responses for Hepatocellular Carcinoma**
Dr. Pil Soo Sung (Korea)
- 17:10-17:25 18-5 **The Prediction Model of HBV-HCC During Anti-viral Therapy**
Dr. Hong You (China)
- 17:25-17:40 Discussion Time

Day 2: December 18 (Saturday) 2021

Room 3

8:00-9:00 Morning Seminar (5) (Sponsored by AstraZeneca)

Chair: Dr. Hiroo Imazu (Japan)

Treatment Strategies for Acid Related Disease in Primary Care-Based on Clinical Practice Guidelines for GERD 2021 Dr. Akihito Nagahara (Japan)

9:10-10:34 Oral Free Papers (3)

Chairs: Dr. Shinya Maekawa (Japan)/Dr. Masahito Shimizu (Japan)/Dr. Katsutoshi Tokushige (Japan)

- 9:10-9:17 #10008 **Contribution of dMMR to Accumulation of Somatic Mutations at Different Stages of HCC Development**
Dr. Masayuki Ueno (Japan)
- 9:17-9:24 #10033 **Genetic Discrimination between Multicentric Occurrence and Intrahepatic Metastasis in Multifocal HCC**
Dr. Yuji Iimuro (Japan)
- 9:24-9:31 #10015 **An Assistive Computational Tool for Defining the Segmental Anatomy of the Liver**
Dr. Harvey Ho (New Zealand)
- 9:31-9:38 #10035 **The Protective Role of DNA Methyltransferase 3B Against Inflammatory Hepatocarcinogenesis**
Dr. Eriko Iguchi (Japan)
- 9:38-9:45 #10060 **Utility of AFP, AFP-L3, and PIVKA-II for Hepatocellular Carcinoma Surveillance**
Dr. Supot Nimanong (Thailand)
- 9:45-9:52 #10062 **Natural Killer Cells Putative Role in Patients with HCV-Related Hepatocellular Carcinoma**
Dr. Mohamed Abdel-Samiee (Egypt)
- 9:52-9:59 #10076 **Let-7a and Let-7i as Biomarkers for CHC Patients with HCC Risk after Anti-viral Treatment**
Dr. Ming-Lung Yu (Taiwan)
- 9:59-10:06 #10009 **Post-treatment Cell-free DNA as a Predictive Biomarker in Systemic Therapy for HCC**
Dr. Takuma Nakatsuka (Japan)
- 10:06-10:13 #10026 **The Combination of ALBI and PT Predict Liver Dysfunction after TACE for HCC within Up-to-7 Criteria**
Dr. Hiroaki Takaya (Japan)
- 10:13-10:20 #10063 **MicroRNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients**
Dr. Mohamed Abdel-Samiee (Egypt)

10:20-10:27 #10079 **Analysis of Sarcopenia in Patients with BCLC Stage B HCC who Received Atezolizumab Plus Bevacizumab**

Dr. Hiroaki Matsumoto (Japan)

10:27-10:34 #10080 **The Simple Product of Albumin and Platelets Indicates the Stage of Liver Fibrosis and Prognosis**

Dr. Koji Fujita (Japan)

11:00-12:00 Educational Seminar (2) (Sponsored by AbbVie GK)

Chair: Dr. Junko Tanaka (Japan)

SVR & HCV-related HCC

Dr. Yoshinari Asaoka (Japan)

HCV Eradication in the SDGs Era

Dr. Hironao Okubo (Japan)

On-site Poster Session Program

Day 2: December 18 (Saturday) 2021 at 13:40-14:20

Room 4

On-Site Poster Session Group 1

Chair: Dr. Hirayuki Enomoto (Japan)

13:40-13:45

#10027 Hepatoma-derived Growth Factor as a Potential Therapeutic Target for Hepatocellular Carcinoma

Dr. Hirayuki Enomoto (Japan)

13:45-13:50

#10034 Iron Chelator Deferasirox Alters Sorafenib-induced Programmed Cell Deaths of Hepatoma Cells

Dr. Wataru Jomen (Japan)

13:50-13:55

#10052 Combination Therapy with Lenvatinib and RFA for CP A Patients with HCC Exceeding up-to-7

Criteria

Dr. Kazushi Numata (Japan)

13:55-14:00

#10088 Examination of the Detectability of Spoke Wheel Pattern by Contrast Ultrasonography in FNH

Dr. Masahiro Ogawa (Japan)

14:00-14:05

#10011 Bezafibrate Treatment is Associated with Reduced Risk for Development of HCC in Patients with PBC

Dr. Atsushi Tanaka (Japan)

14:05-14:10

#10031 Safety of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma

Dr. Hiroshi Numao (Japan)

On-site Poster Session Group 2

Chair: Dr. Fumitaka Suzuki (Japan)

13:40-13:45

#10010 Real Impact of Tumor Marker AFP and PIVKA-II in Detecting Very Small Hepatocellular Carcinoma

Dr. Akito Nozaki (Japan)

13:45-13:50

#10054 Circulating IGFBP-1 Provides Resistance to Molecular Targeted Agent in Hepatocellular Carcinoma

Dr. Hiroyuki Suzuki (Japan)

13:50-13:55

#10081 Relationship between Serum Kynurenine Level and Prognosis of Patients with Hepatocellular Carcinoma

Dr. Shigemune Bekki (Japan)

13:55-14:00

#10082 Measurement of Renal Vein and IVC in Patients with Cirrhotic Ascites and Congestive Liver

Dr. Masahiro Kaneko (Japan)

14:00-14:05

#10017 Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

Dr. Naoki Matsumoto (Japan)

14:05-14:10

- #10078 **An Autopsy Case of Ruptured Hepatocellular Carcinoma Following Administration of Lenvatinib**
Dr. Kumichika Uchida (Japan)

On-site Poster Session Group 3

Chair: Dr. Ryota Masuzaki (Japan)

13:40-13:45

- #10083 **A Case of Mortality from an Incidental Intrahepatic Cholangiocarcinoma with Severe Cholecystitis**
Dr. Yoshie Kadota (Japan)

13:45-13:50

- #10041 **Laparoscopic Surgery could be Most Frequently Employ as a Treatment for HCC in SVR era**
Dr. Shuntaro Obi (Japan)

13:50-13:55

- #10044 **ATZ+BEV Therapy can Control Disease Activity in Patients Who Do Not Respond to Lenvatinib**
Dr. Shuntaro Obi (Japan)

13:55-14:00

- #10038 **Incidence of HCC is Quite Different Depending on the History of HCC; A Prospective Study by 600 SVRs**
Dr. Shuntaro Obi (Japan)

14:00-14:05

- #10039 **Beware of Carcinogenesis Other Than HCC; A Prospective Study by 600 SVRs**
Dr. Shuntaro Obi (Japan)

14:05-14:10

- #10040 **Risk Factors for Occurrence of HCC after DAA Therapy; A Prospective Study by 600 SVRs**
Dr. Shuntaro Obi (Japan)

14:10-14:15

- #10043 **Is Liver Carcinogenesis after SVR IM or MC? By Analysis of Gene Profiles**
Dr. Shuntaro Obi (Japan)

On-site Poster Session Group 4

Chair: Dr. Makiko Taniai (Japan)

13:40-13:45

- #10021 **Major Signaling Pathway in Hepatocellular Carcinoma and Drug-matched Variants**
Dr. Kenji Amemiya (Japan)

13:45-13:50

- #10065 **Phenotypic and Genetic Features of Multiple Nodules in HCC Based on Tumor Evolutionary Trait**
Dr. Yosuke Hirotsu (Japan)

13:50-13:55

- #10019 **Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus**
Dr. Shohei Komatsu (Japan)

13:55-14:00

- #10084 **Conversion Surgery for Advanced Hepatocellular Carcinoma after Lenvatinib, a Case Report**
Dr. Kazuki Kato (Japan)

14:00-14:05

- #10007 **TACE with Cisplatin Versus Epirubicin for Hepatocellular Carcinoma, a Randomised Controlled Trial**
Dr. Osamu Aramaki (Japan)

14:05-14:10

- #10070 **Examination of the Effect of Embolization of Corona Enhancement Area on Local Tumor Recurrence**
Dr. Yukinobu Watanabe (Japan)

On-site Poster Session Group 5

Chair: Dr. Shinpei Sato (Japan)

13:40-13:45

- #10085 **Experience of Antiviral Therapy in Patients Co-infected with HIV and Hepatitis Virus**
Dr. Yuki Haga (Japan)

13:45-13:50

- #10036 **Levocarnitine Suppresses Lenvatinib-related Sarcopenia in Hepatocellular Carcinoma Patients**
Dr. Hironao Okubo (Japan)

13:50-13:55

- #10025 **Clinical Features of Systemic Treatment in Japan**
Dr. Takaaki Tanaka (Japan)

13:55-14:00

- #10022 **Clinical Trend of Japanese Patients with HCC in Progression of Aging Society: Clinical Role of RFA**
Dr. Shota Izumi (Japan)

14:00-14:05

- #10037 **Two Cases of RFA for HCC in the Caudate Lobe; an Emerging Technique with Using Guided Needle Under CT**
Dr. Sae Yumita (Japan)

14:05-14:10

- #10030 **The Cancer Risk in PSC and Ulcerative Colitis from 26 Years Retrospective Cohort Study in Japan**
Dr. Takashi Taida (Japan)

On-site Poster Session Group 6

Chair: Dr. Shintaro Yamazaki (Japan)

13:40-13:45

- #10053 **Stereotactic Body Radiotherapy for Early-stage Hepatocellular Carcinoma: A Single-Center Experience**
Dr. Shunsuke Okuyama (Japan)

13:45-13:50

- #10014 **Impact of Postoperative Complications on Survival of Hepatocellular Carcinoma Patients**
Dr. Hisashi Nakayama (Japan)

13:50-13:55

- #10028 **Surgical Resection for Hepatocellular Carcinoma with Major Vascular Invasion**
Dr. Shintaro Yamazaki (Japan)

13:55-14:00

- #10032 **Impact of Patient Age on Outcome after Resection for Hepatocellular carcinoma**
Dr. Masaharu Harada (Japan)

14:00-14:05

#10056 **Transient High Transaminase Elevation Does Not Affect on Short Term Outcomes after Liver Resection**
Dr. Yusuke Mitsuka (Japan)

14:05-14:10

#10003 **Sex-related Differences in Predictors of HCC Incidence after DAA Therapy in Patients with HCV**
Dr. Takao Watanabe (Japan)

E-Poster Session Program

E-Poster Presentation will be available through Website of APASL Oncology 2021

at <http://www.apasl-oncology2021.org/>

- #10001 **FBL is the Hub Gene of Pulmonary Metastasis in Hepatocellular Carcinoma**
Dr. Wen-Rui Wu (China)
- #10002 **Everolimus Protect IRI Through the Effect of Treg**
Dr. Li Zhu (China)
- #10013 **Durability of SVR in GT3 and GT6 Patients Treated with SOF/VEL with/without RBV from China**
Dr. Huagang Xiong (China)
- #10016 **Clinical Characteristics and Survival Analysis of Patients with HCC after HBV Negative**
Dr. Hong Li (China)
- #10018 **Characteristics of Genomic Profile of Hepatocellular Carcinoma after Sustained Virologic Response**
Dr. Hiroshi Ohyama (Japan)
- #10042 **A Case of Primary Biliary Cholangitis Undergoing RFA for Liver Metastasis of Cervical Cancer**
Dr. Ken Nogami (Japan)
- #10048 **Development of Novel Therapeutic Agents for HCC by Suppressing Soluble MICA through ADAM9 Inhibition**
Dr. Keita Ogawa (Japan)
- #10050 **Impacts of EZH2 Inhibitor UNC1999 on Tumor and Tumor Microenvironment in Hepatocellular Carcinoma**
Dr. Junjie Ao (Japan)
- #10051 **Efficacy of Sorafenib and Radiotherapy vs Sorafenib/Radiotherapy Monotherapy: A Systematic Review**
Dr. Rivaldo S. Heriyanto (Indonesia)
- #10055 **The Effect of Glucosylceramide Synthase Inhibitor on Liver Fibrosis Regression**
Dr. Terunao Iwanaga (Japan)
- #10057 **Stereotactic Body Radiation Therapy for Early-stage Hepatocellular Carcinoma**
Dr. Shigeki Yano (Japan)
- #10059 **Combination Therapy for Multiple HCC with Tyrosine Kinase Inhibitor and Radiofrequency Ablation**
Dr. Keita Maki (Japan)
- #10068 **Macrotrabecular Massive Feature in Tumor is Associated with a Higher Risk of the Recurrence of HCC**
Dr. Hyun Woong Lee (Korea)
- #10071 **Acidic Microenvironment Aggravates HIRI by Modulating M1-Polarization by PPAR-gama Signal**
Dr. Wei Ding (China)
- #10072 **Protection Mechanism of DDIT4 S-Nitrosylation in ROS**
Dr. Yunfei Duan (China)
- #10074 **Molecular Mechanism of CCL7 by BRG1 in Liver Injury**
Dr. Yunjie Lu (China)
- #10075 **Dynamic Gut Microbiome Affects the Efficacy of PD-1-based Immunotherapy in Hepatocellular Carcinoma**
Dr. Chan Xie (China)
- #10086 **Regorafenib for Taiwanese Patients with Unresectable HCC after Sorafenib Failure**
Dr. Ming-Lung Yu (Taiwan)
- #10087 **Education and information sharing method for the coming era in ablation**
Dr. Maki Tobar (Japan)
- #10089 **MWA vs. RFA in Intermediate Stage Hepatocellular Carcinoma: A Retro-prospective Study**
Dr. Diana Alcantara Babaran (Philippines)

人々のより良い健康のために。

ベーリンガーインゲルハイムは、株式を公開しない企業形態の特色を生かし、長期的な視点で、医薬品の研究開発、製造、販売を中心に事業を世界に展開している製薬企業です。

日本ベーリンガーインゲルハイム株式会社 主要製品

直接トロンビン阻害剤

薬価基準収載

プラザキサ[®] 75mg
カプセル 110mg

ダビガトランエテキシラートメタンサルホン酸塩製剤

処方箋医薬品

(注意・医師等の処方箋により使用すること)

Prazaxa[®] Capsules 75mg・110mg

選択的SGLT2阻害剤・2型糖尿病治療剤

薬価基準収載

ジャディアンス[®] 錠 10mg
25mg

エンパグリフロジン製剤

処方箋医薬品

(注意・医師等の処方箋により使用すること)

Jardiance[®]

長時間作用性吸入気管支拡張剤

薬価基準収載

スピリーバ[®] 1.25 μ gレスピマッド 60吸入
2.5 μ gレスピマッド 60吸入

チオトロピウム臭化物水和物製剤

処方箋医薬品

(注意・医師等の処方箋により使用すること)

SPIRIVA[®]

抗悪性腫瘍剤 / チロシンキナーゼ阻害剤

薬価基準収載

ジオトリフ[®] 錠 20mg
30mg
40mg
50mg

アフチニブマレイン酸塩製剤

新薬、処方箋医薬品

(注意・医師等の処方箋により使用すること)

Giotrif[®] Tablets 20mg・30mg・40mg・50mg

胆汁排泄型選択的DPP-4阻害剤・2型糖尿病治療剤

薬価基準収載

トラゼンタ[®] 錠 5mg

リナグリプチン製剤

処方箋医薬品

(注意・医師等の処方箋により使用すること)

Trazenta[®] Tablets 5mg

選択的SGLT2阻害剤 / 胆汁排泄型選択的DPP-4阻害剤配合剤・2型糖尿病治療剤

薬価基準収載

トラディアンス[®] 配合錠 AP
BP

エンパグリフロジン / リナグリプチン配合錠

処方箋医薬品

(注意・医師等の処方箋により使用すること)

Trandiance[®] Combination Tablets AP・BP

COPD治療配合剤

薬価基準収載

スピオルト[®] レスピマッド[®]
28吸入 / 60吸入

チオトロピウム臭化物水和物 / オロダテロール塩酸塩製剤

処方箋医薬品

(注意・医師等の処方箋により使用すること)

SPIOLTO[®]

チロシンキナーゼ阻害剤 / 抗線維化剤

薬価基準収載

オフエブ[®] 100mg
カプセル 150mg

ニンテダニブエタンサルホン酸塩製剤

新薬、処方箋医薬品

(注意・医師等の処方箋により使用すること)

OFEV[®] Capsules 100mg・150mg

※効能・効果、用法・用量、警告、禁忌を含む使用上の注意等につきましては製品添付文書をご参照下さい。

日本ベーリンガーインゲルハイム株式会社

〒141-6017 東京都品川区大崎 2-1-1 ThinkPark Tower
資料請求先: 日本ベーリンガーインゲルハイム株式会社 DIセンター
☎ 0120-189-779 (受付時間: 9:00~18:00 土・日・祝・祭日・弊社休業日を除く)



Boehringer
Ingelheim

2018年11月作成



新しい細胞治療を通じて、 生活の質を高めること

皮下脂肪組織には、脂肪組織由来再生(幹)細胞(ADRC)という間質血管細胞群が含まれています※¹。

セルーション セルセラピーキットは患者から採取した脂肪組織より細胞を分離・洗浄し、安定的に採取するための単回使用のキットです。

特徴

非培養

最適化された細胞分離工程

滅菌閉鎖系回路

同一手術内完結型

セルーション セルセラピーキット 高度管理医療機器



販売名:セルーション セルセラピーキット

医療機器製造販売承認番号: 23000BZX00357000

品番:CK001



併用医療機器

販売名:セルーション 遠心分離器

品番:CC1

医療機器製造販売届出番号: 13B1X10155000001

※1 Kesten S, Fraser JK. Autologous Adipose Derived Regenerative Cells: A Platform for Therapeutic Applications. Surg Technol Int. 2016 Oct 26;29:38-44. PMID: 27466873.

お問い合わせ

☎ 03-6860-5700

✉ contactjp@cytori-jp.com



サイトリ・セラピューティクス株式会社

〒100-0004
東京都千代田区大手町一丁目1番1号 大手町パークビルディング
TEL: 03-6860-5700 FAX: 03-6860-5705

第一種医療機器製造販売業 13B1X10155

RM-014-LIT-0415-C-JP

INVENTING FOR LIFE

人々の生命を救い
人生を健やかにするために、挑みつづける。

最先端の医薬品の創造。それは長く険しい道のりです。
懸命な研究開発の99%以上は実を結ばない現実。
でも、決してあきらめない。
あなたや、あなたの大切な人の「いのち」のために、
革新的な新薬とワクチンの発見、開発、提供を
私たちは続けていきます。



MSD製薬

INVENTING FOR LIFE



効能・効果、用法・用量、禁忌を含む使用上の注意等については添付文書をご参照ください。



製造販売元[文献請求先及び問い合わせ先]
あすか製薬株式会社
東京都港区芝浦二丁目5番1号

販売
武田薬品工業株式会社
大阪府中央区道修町四丁目1番1号

提携
Alfasigma S.p.A.



難吸収性リファマイシン系抗菌薬 処方箋医薬品^(注) 薬価基準収載

リフキシマ[®]錠200mg

RIFXIMA[®] TABLETS 200mg

リファキシミン製剤


(注) 注意—医師等の処方箋により使用すること

2020年2月作成

Designed for 3Fr SYSTEM

NEO Cerisier[®]SS

Thinner distal segment to increase flexibility
Neo Cerisier SS Micro Catheter



■ Neo CerisierSS Specifications

Product Name	Product Code	Description	Compatible Guidewire	JAN Code
Neo CerisierSS 110cm	XX0341	NCS-110S-SS-N	0.014inch	4560249950963
Neo CerisierSS 135cm	XX0342	NCS-135S-SS-N	0.014inch	4560249950970



MEDIKIT Co.,Ltd.

13-2, Yushima, 1-chome, Bunkyo-Ku, Tokyo, 113-0034 Japan

Phone: 81-3-3839-8633 Fax: 81-3-3839-3978

URL: www.medikit.co.jp/english/

Manufacturer

TOGO MEDIKIT Co.,Ltd.



処方箋医薬品：注意－医師等の処方箋により使用すること

慢性便秘症治療薬

モビコール®配合内用剤LD

MOVICOL® LD 「モビコール」及び MOVICOL は、Norgineグループの登録商標です。

薬価基準収載

効能又は効果、用法及び用量、禁忌を含む使用上の注意等については添付文書をご参照ください。

製造販売元

 **EAファーマ株式会社**
東京都中央区入船二丁目1番1号

販売く文献請求先及び問い合わせ先

 **持田製薬株式会社**
東京都新宿区四谷1丁目7番地
TEL 0120-189-522 (くすり相談窓口)

2021年1月作成 (N7)



健康づくりは幸せづくり

病気になると自分で懸命に治ろうとする体。

そんな健気で優しいあなたの体の声に耳を澄まして

薬を研究・開発してきたゼリア新薬。

消化器系を中心とした医療用医薬品から

コンドロイチンをはじめとする

コンシューマーヘルスケア事業まで。

すべての人に健康でいきいきと生活してほしいという願いは

今、さまざまな取り組みとなって広がっています。

 **ゼリア新薬工業株式会社** www.zeria.co.jp

Today Astellas is working to meet
unmet medical needs.

All around the world there are diseases

for which no medicine has been developed.

Such unmet medical needs are the

battleground of Astellas.

Our mission is to change tomorrow

for millions of lives, one drug at a time.

www.astellas.com/en/

Changing tomorrow

 **astellas**
Astellas Pharma Inc.



処方箋医薬品^{注)}
クロライドチャンネルアクチベーター
アミティーザ[®]カプセル 12 μ g 24 μ g
ルビプロストンカプセル **Amitiza[®] Capsules** 12 μ g 24 μ g
注) 注意一医師等の処方箋により使用すること

「効能・効果」、「用法・用量」、「禁忌を含む使用上の注意」、「効能・効果に関連する使用上の注意」、「用法・用量に関連する使用上の注意」等については添付文書をご参照ください。

製造販売元 **マイランEPD合同会社**
東京都港区虎ノ門5丁目11番2号
〔資料請求先〕 ぐすり相談室 フリーダイヤル 0120-938-837

 **VIATRIS**

2021年1月作成

PHILIPS

Ingenia Elition 3.0T

A revolutionary breakthrough in diagnostic quality and speed

MRI検査の質と検査スピードの追及が
患者の診療と医療従事者の環境改善をサポートします

innovation  you

株式会社フィリップス・ジャパン
www.philips.co.jp/healthcare

Ingenia Elition 3.0T 超電導磁気共鳴画像診断装置

販売名: フィリップス Elition 3.0T
医療機器認証番号: 230ACBZX000090000
設置管理医療機器 / 特定保守管理医療機器
管理医療機器
記載されている製品名などの固有名称は、Koninklijke Philips N.V.の
商標または登録商標です。
© 2018 Philips Japan, Ltd.



ウィルソン病治療剤（銅吸収阻害剤）・低亜鉛血症治療剤

薬価基準収載



ノベルジン®錠 25mg・50mg

酢酸亜鉛水和物製剤 NOBELZIN® Tablets 25mg・50mg

薬価基準収載

ノベルジン®顆粒 5%

発売準備中

酢酸亜鉛水和物製剤 NOBELZIN® Granules 5%

劇薬、処方箋医薬品^注 注) 注意 - 医師等の処方箋により使用すること ®ノーベルファーマ株式会社 登録商標

【効能又は効果】、【用法及び用量】、【禁忌】、【重要な基本的注意】等については、製品添付文書をご参照ください。

Nobelpharma

製造販売元
ノーベルファーマ株式会社
東京都中央区新川 1-17-24

【資料請求先・製品情報お問い合わせ先】
ノーベルファーマ株式会社 カスタマーセンター
フリーダイヤル：0120-003-140

2021年5月作成



持続性がん疼痛治療剤 薬価基準収載

ナルサス錠

2mg 6mg
12mg 24mg

劇薬、麻薬、処方箋医薬品：注意—医師等の処方箋により使用すること
ヒドロモルフォン塩酸塩徐放錠

がん疼痛治療剤 薬価基準収載

ナルラピド錠

1mg
2mg
4mg

劇薬、麻薬、処方箋医薬品：注意—医師等の処方箋により使用すること
ヒドロモルフォン塩酸塩錠

がん疼痛治療用注射剤 薬価基準収載

ナルベイン注

2mg
20mg

劇薬、麻薬、処方箋医薬品：注意—医師等の処方箋により使用すること
ヒドロモルフォン塩酸塩注

※「効能又は効果」、「用法及び用量」、「禁忌を含む使用上の注意」等については添付文書をご参照ください。

製造販売元

第一三共プロファーマ株式会社
東京都中央区日本橋本町3-5-1



販売元（文献請求先及び問い合わせ先を含む）

第一三共株式会社
東京都中央区日本橋本町3-5-1

2021年4月作成



劇薬・処方箋医薬品（注意—医師等の処方箋により使用すること）

エンドセリン受容体拮抗薬

薬価基準収載

オプスミット錠10mg

一般名：マシテンタン／Macitentan

●「効能・効果」、「用法・用量」、「禁忌を含む使用上の注意」等につきましては、製品添付文書をご参照ください。



製造販売元（文献請求先・製品情報お問い合わせ先）

ヤンセンファーマ株式会社
〒101-0065 東京都千代田区西神田3-5-2
www.janssen.com/japan
www.janssenpro.jp（医薬品情報）

販売提携先
日本新薬株式会社
〒601-8550 京都市南区吉祥院西ノ庄門口町14

©Janssen Pharmaceutical K.K. 2015-2020


2020年7月作成

TERUMO
INTERVENTIONAL
SYSTEMS

3D形状の太径コイルとインナーハイドロゲルで
より確実な血流抑制を追求。

AZUR[®] CX35

膨潤型血管内塞栓用コイル



一般的名称：中心循環系血管内塞栓促進用補綴材 販売名：テルモ末梢血管塞栓用コイルシステム AZUR CX35 医療機器承認番号：22800BZX00396

AZUR CX35はテルモ末梢血管塞栓用コイルシステムAZUR CX35のペットネームです。
※本製品の詳細は添付文書をご参照ください。

製造販売業者 テルモ株式会社 〒151-0072 東京都渋谷区幡ヶ谷2-44-1 www.terumo.co.jp

※写真は実際の大きさと異なります。

TERUMOはテルモ株式会社の商標です。
テルモ、AZURはテルモ株式会社の登録商標です。
©テルモ株式会社2017年3月

力強く、前へ

その一歩が、より良い未来の医療へ繋がると信じて。
この先の100年も、熱い想いで明日の医療を変えていく。
私たちはテルモです。

Stride Ahead
100th

2021年、テルモは創立100周年を迎えます。

テルモ株式会社

100周年記念サイト
www.terumo.co.jp/100th/



TERUMO



自動分析装置用試薬
汎用検査用亜鉛キット

アキュラスオート Zn

臨床的意義

亜鉛(Zn)はDNAポリメラーゼを始めとする100種類以上の酵素に含まれ、タンパク質合成、ホルモン活性発現など、正常な生命維持に不可欠な微量元素です。発生・成長、組織の修復、骨の維持、生殖・感覚・食欲・免疫機能など生体内の様々な機能が亜鉛に依存されて維持されており、亜鉛欠乏の検出は疾患の治療に結びつく重要な情報の一つとなります。

亜鉛欠乏の症状：味覚・嗅覚障害、食欲低下、皮膚炎、脱毛症、創傷治癒の遅延、気力・活力低下 など

アキュラスオート Zn の特長

＊ 血清、血漿および尿中の亜鉛濃度を測定できます

＊ 検体の前処理を必要としません

＊ 原子吸光法との相関が良好です

$y=0.976x-0.7$ (n=60、血清検体)
x: 原子吸光法 y: 本品 r=0.996



■ 包装単位 ■

統一商品コード	品名	識別記号	規格	統一商品コード	品名	識別記号	規格
326054268	アキュラスオート Zn		12 mL × 2	326078059	アキュラスオート Zn		20.0 mL × 2
326054275	R-Ⅰ 緩衝液		5.5 mL × 2		R-Ⅰ 緩衝液	(E) (20)	8.9 mL × 2
	R-Ⅱ 呈色液				R-Ⅱ 呈色液		
326062942	アキュラスオート Zn		28.6 mL × 2	*「R-Ⅰ 緩衝液」、「R-Ⅱ 呈色液」は別売です。但し、識別記号 HLS、(55)、(E) (20) はセット規格です。			
	R-Ⅰ 緩衝液	HLS	12.2 mL × 2	<別売品>			
	R-Ⅱ 呈色液			326052936	Zn標準液 (200 μg/dL)		10 mL × 1
326062478	アキュラスオート Zn		20 mL × 2	326055722	亜鉛コントロール (100 μg/dL)		10 mL × 1
	R-Ⅰ 緩衝液	(55)	9.5 mL × 2	326081127	亜鉛コントロール (H)		10 mL × 1
	R-Ⅱ 呈色液						

亜鉛を自動分析装置で測定しませんか？

製造販売元  株式会社シノテスト

神奈川県相模原市南区大野台 4-1-93

<https://www.shino-test.co.jp>

《問い合わせ先》

株式会社シノテスト カスタマーサポート

TEL 0120-66-1141

FAX 042-753-1892



The Asian Pacific Association for the Study of the Liver



APASL Oncology 2022

APASL Single Topic Conference

"Liver Cancer : Clinical and Basic Research"

2022
September

1 - 3
(Thurs) (Sat)

President

Tsutomu Masaki, MD.

Professor and Chairman,
Department of Gastroenterology and Neurology,
Faculty of Medicine, Kagawa University

Venue

Hotel Clement Takamatsu

Takamatsu-city, Kagawa, Japan

www.apaslsc-takamatsu2022.org

Scientific Secretariat

Department of Gastroenterology and Neurology,
Faculty of Medicine, Kagawa University

Congress Secretariat

APASL STC Takamatsu 2022 Congress Secretariat
c/o Academia Support Japan
Tel: +81-3-6380-0102 Fax: +81-3-6380-0103
Email: info@apaslsc-takamatsu2022.org



Nexavar® 200mg
Sorafenib Tosilate (anticancer agent / kinase inhibitor)
Deleterious / Prescription drug*
Listing in the National Health Insurance drug price list
*Caution : Use under prescription from a physician, etc.



Stivarga®
(regorafenib) tablets

Stivarga® 40mg
Regorafenib Hydrate (anticancer agent / kinase inhibitor)
Deleterious / Prescription drug*
Listing in the National Health Insurance drug price list
*Caution : Use under prescription from a physician, etc.

Please refer to the package insert for the indications, dosage and administration,
and precautions including box warnings and contraindications



Bayer

Distributed and marketed by

Bayer Yakuhin, Ltd.

4-9,Umeda 2-chome
kita-ku,Osaka 530-0001,JAPAN
<https://byl.bayer.co.jp/>